TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25031289

Group type: EXPERIMENTAL
Intervention: Gentamicin 240 mg intramuscularly plus Azithromycin 2 g orally
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg orally plus Azithromycin 2 g orally
Number of subjects: 401
Study: 23057354

Group type: EXPERIMENTAL
Intervention: Tubal reconstruction after laparoscopic tubal pregnancy operation
Number of subjects: 63

Group type: COMPARATOR
Intervention: Simple laparoscopic tubal pregnancy operation
Number of subjects: 63
Study: 20480839

Group type: EXPERIMENTAL
Intervention: Ilioinguinal neurectomy group
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Iliohypogastric neurectomy group
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Neurectomies group
Number of subjects: 240

Group type: COMPARATOR
Intervention: All-nerve preservation group
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 240
Study: 18686759

Group type: EXPERIMENTAL
Intervention: Active trainees (compliant with training regimens)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inactive trainees (non-compliant with training regimens)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study: 15657157

Group type: EXPERIMENTAL
Intervention: Gemfibrozil, niacin, and cholestyramine
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 12687853

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 986

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 986

Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 986

Group type: COMPARATOR
Intervention: Nonsurvivors
Number of subjects: 986

Group type: COMPARATOR
Intervention: Victims of any mode of death
Number of subjects: 986

Group type: COMPARATOR
Intervention: Patients with any mode of death
Number of subjects: 986
Study: 10575071

Group type: EXPERIMENTAL
Intervention: Different movement amplitudes and types of holds
Number of subjects: 0
Study: 8678278

Group type: EXPERIMENTAL
Intervention: Alcuronium 0.25 mg/kg with thiopentone 7 mg/kg i.v. (Group A)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg with thiopentone 7 mg/kg i.v. (Group C)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Alcuronium 0.25 mg/kg with propofol TIVA (Group B)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg with propofol TIVA (Group D)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg with thiopentone (Group E)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Propofol 1% 3 mg/kg given at the beginning of recovery phase
Number of subjects: 43
Study: 1359745

Group type: EXPERIMENTAL
Intervention: Zileuton 800 mg b.i.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2870809

Group type: EXPERIMENTAL
Intervention: Ciclopirox olamine 1% applied twice daily for 28 days
Number of subjects: 148

Group type: COMPARATOR
Intervention: Clotrimazole
Number of subjects: 148

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 148
Study: 29336265

Group type: EXPERIMENTAL
Intervention: Topical Plantavera gel
Number of subjects: 40

Group type: COMPARATOR
Intervention: Topical Placebo gel
Number of subjects: 40
Study: 28082115

Group type: EXPERIMENTAL
Intervention: EndoCuff-assisted colonoscopy (EAC)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 288
Study: 26079901

Group type: EXPERIMENTAL
Intervention: TEP under general anesthesia
Number of subjects: 384

Group type: COMPARATOR
Intervention: LLA using local anesthesia
Number of subjects: 384
Study: 24655487

Group type: EXPERIMENTAL
Intervention: Oily fish (salmon) providing 274 mg EPA + 671 mg DHA per day
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Fish oil supplement providing 396 mg EPA + 250 mg DHA per day
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Oily fish (salmon)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Fish oil supplement
Number of subjects: 33

Group type: COMPARATOR
Intervention: Both interventions (salmon and fish oil)
Number of subjects: 33
Study: 22034636

Group type: EXPERIMENTAL
Intervention: Sulodexide
Number of subjects: 1248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1248
Study: 20451454

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (18 g/m²)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Low-dose cytarabine (2 g/m²)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Induction 2
Number of subjects: 232
Study: 18504369

Group type: EXPERIMENTAL
Intervention: Electrogastrography (EGG) examination in patients with vascular and paralytic ileus
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Electrogastrography (EGG) examination in patients with obstructive ileus
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Patients with obstructive ileus and bradygastria
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: C-reactive protein concentration in patients with obstructive ileus
Number of subjects: 54
Study: 15966088

Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair (EVAR)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Surveillance (UKsurveil)
Number of subjects: 312
Study: 12586512

Group type: EXPERIMENTAL
Intervention: 30 mg 'Fast' formulation (12 h)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 30 mg 'Slow' formulation (24 h)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 2x15 mg immediate release tablets (12 h interval)
Number of subjects: 18
Study: 10669909

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of rifampicin and isoniazid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Separate formulations of rifampicin and isoniazid
Number of subjects: 12
Study: 8915147

Group type: EXPERIMENTAL
Intervention: Combination patch testing (two different sets of five patches each containing combinations of three or four allergens per patch)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Conventional patch testing (17 standard allergens applied individually)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Combination patch testing (combination patches 1 and 2)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Conventional patch testing
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Combination patch testing
Number of subjects: 137
Study: 1855691

Group type: EXPERIMENTAL
Intervention: Combination tablet of cimetidine 200 mg and alginic acid 500 mg, taken one tablet four times daily (increased to two tablets four times daily if response was unsatisfactory after six weeks)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Standard dosage of cimetidine 400 mg four times daily
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Combination tablet of cimetidine 200 mg and alginic acid 500 mg
Number of subjects: 312
Study: 6817188

Group type: EXPERIMENTAL
Intervention: Showering
Number of subjects: 82

Group type: COMPARATOR
Intervention: Non-showering
Number of subjects: 82
Study: 30726347

Group type: EXPERIMENTAL
Intervention: Cohort A (n=2,143)
Number of subjects: 2796

Group type: EXPERIMENTAL
Intervention: Cohort B (n=298)
Number of subjects: 2796

Group type: EXPERIMENTAL
Intervention: Cohort C (n=355)
Number of subjects: 2796

Group type: EXPERIMENTAL
Intervention: Longitudinal follow-up (2010)
Number of subjects: 2796

Group type: EXPERIMENTAL
Intervention: Blood collection and accelerometer measurements
Number of subjects: 2796
Study: 29544551

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT) - intensive, group, and independent methods
Number of subjects: 720

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 720
Study: 26805535

Group type: EXPERIMENTAL
Intervention: Simulated circadian clock group (study group)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group in simulated circadian clock group
Number of subjects: 70

Group type: COMPARATOR
Intervention: Propofol group in simulated circadian clock group
Number of subjects: 70
Study: 25307535

Group type: EXPERIMENTAL
Intervention: Achieved LDL target (< 2.0 mmol/L)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Statin use
Number of subjects: 448

Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 448
Study: 23041150

Group type: EXPERIMENTAL
Intervention: Astragaloside IV (AS-IV)
Number of subjects: 0
Study: 20424829

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (SHAM)
Number of subjects: 14
Study: 18022000

Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC) 300 mg along with hydration (500 mL multielectrolyte fluid)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Hydration (500 mL multielectrolyte fluid) only
Number of subjects: 112
Study: 16146256

Group type: EXPERIMENTAL
Intervention: 0.05 mL/kg nebulized L-epinephrine
Number of subjects: 39

Group type: COMPARATOR
Intervention: 0.5 mL/kg nebulized L-epinephrine
Number of subjects: 39
Study: 12163671

Group type: EXPERIMENTAL
Intervention: Oral tracer protocol
Number of subjects: 5

Group type: COMPARATOR
Intervention: Intravenous (IV) tracer protocol
Number of subjects: 5
Study: 10485962

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg oral)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 24
Study: 7677832

Group type: EXPERIMENTAL
Intervention: Neck suction stimulation of carotid baroreceptors at 0.1 Hz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neck suction stimulation of carotid baroreceptors at 0.2 Hz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resting state power spectrum analysis
Number of subjects: 0
Study: 2803121

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ampicillin and Metronidazole
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ampicillin and Sulbactam
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 30208393

Group type: EXPERIMENTAL
Intervention: Training in Supported Conversation for Adults with Aphasia
Number of subjects: 80

Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 80
Study: 26672413

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal appliance (NPA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mandibular repositioning splint (MRS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 60
Study: 22410476

Group type: EXPERIMENTAL
Intervention: tDCS to left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: tDCS to left temporo-parietal cortex (TPC)
Number of subjects: 16
Study: 21681507

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 18356323

Group type: EXPERIMENTAL
Intervention: High-Protein (HP) lunch (25%E protein, 45%E carbohydrate, 30%E fat)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Appropriate Protein (AP) lunch (10% energy protein, 60%E carbohydrate, 30%E fat)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-Protein (HP) lunch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Appropriate Protein (AP) lunch
Number of subjects: 0
Study: 17058887

Group type: EXPERIMENTAL
Intervention: Modular education program (MASA Program) with patient handout and PowerPoint slides, 2-hour teaching program for three times over six months
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Modular education program (MASA Program)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group received a short introduction to peak-flow meter, asthma diary, and emergency instructions
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study: 15002887

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer/fluoride dentifrice
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard fluoride dentifrice
Number of subjects: 60
Study: 10965648

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 60
Study: 8632624

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rtPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urokinase (UK)
Number of subjects: 0
Study: 6703371

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Meperidine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Naloxone (after fentanyl, morphine, or meperidine)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Naloxone (without narcotics)
Number of subjects: 50
Study: 31678952

Group type: EXPERIMENTAL
Intervention: Mobile phone-supported prevention programme (10-week duration)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 60
Study: 30543702

Group type: EXPERIMENTAL
Intervention: Fruit group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nuts group
Number of subjects: 0
Study: 27124565

Group type: EXPERIMENTAL
Intervention: Family burden assessment using the Infant Toddler Quality of Life Questionnaire (for children <5 years) and the Child Health Questionnaire (for children ≥5 years) at baseline, 3 months, and 12 months post arrest.
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Child functioning assessment using the Vineland Adaptive Behavior Scale II, Pediatric Overall Performance Category, and Pediatric Cerebral Performance Category scales at 3 months post arrest.
Number of subjects: 77
Study: 24424141

Group type: EXPERIMENTAL
Intervention: Surgical ligation and stripping
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation
Number of subjects: 267

Group type: COMPARATOR
Intervention: C2 (simple varicose veins)
Number of subjects: 267

Group type: COMPARATOR
Intervention: C3-4 (soft tissue complications)
Number of subjects: 267
Study: 22711908

Group type: EXPERIMENTAL
Intervention: Class-based delivery strategy
Number of subjects: 5532

Group type: COMPARATOR
Intervention: Age-based delivery strategy
Number of subjects: 5532

Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 5532
Study: 21045096

Group type: EXPERIMENTAL
Intervention: DHA supplementation (2 g/d)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study: 18062595

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 279
Study: 15723894

Group type: EXPERIMENTAL
Intervention: Graded exercise therapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 49
Study: 12409185

Group type: EXPERIMENTAL
Intervention: BoNT/A (100 mouse units, Dysport)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 10210385

Group type: EXPERIMENTAL
Intervention: 5 mg finasteride daily
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 5 mg finasteride daily in men with prostates larger than 40 cc
Number of subjects: 121
Study: 7818120

Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms) added to bupivacaine in spinal anesthesia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms) added to bupivacaine in epidural anesthesia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms) added to bupivacaine in both spinal and epidural anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bupivacaine alone (without clonidine)
Number of subjects: 40
Study: 2103193

Group type: EXPERIMENTAL
Intervention: 5‐isosorbide mononitrate (20 mg)
Number of subjects: 15
Study: 391626

Group type: EXPERIMENTAL
Intervention: 0.025% oxymetazoline ophthalmic solution
Number of subjects: 141

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 141
Study: 31321763

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 72
Study: 28973535

Group type: EXPERIMENTAL
Intervention: Movie containing guns
Number of subjects: 104

Group type: COMPARATOR
Intervention: Movie not containing guns
Number of subjects: 104
Study: 26825288

Group type: EXPERIMENTAL
Intervention: Traditional Birth Attendant (TBA) referral program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (rural control facilities)
Number of subjects: 0
Study: 23307507

Group type: EXPERIMENTAL
Intervention: Standard Colonoscopy (SC)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Colon Capsule Endoscopy (CCE)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standard Colonoscopy (SC) and Colon Capsule Endoscopy (CCE)
Number of subjects: 13
Study: 21979997

Group type: EXPERIMENTAL
Intervention: Supplementation with meso‐zeaxanthin (10.6 mg), lutein (5.9 mg), and zeaxanthin (1.2 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Supplementation with meso‐zeaxanthin, lutein, and zeaxanthin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 17933885

Group type: EXPERIMENTAL
Intervention: Occupational health intervention including consultation and possible referral to specialist treatment.
Number of subjects: 418

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Occupational health intervention (n = 134) with available cost data.
Number of subjects: 418

Group type: COMPARATOR
Intervention: Usual care (control group) with available cost data (n = 138).
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Occupational health intervention.
Number of subjects: 418
Study: 15647491

Group type: EXPERIMENTAL
Intervention: 30 degrees screen-cursor rotation
Number of subjects: 0

Group type: COMPARATOR
Intervention: 30 degrees counter-rotation learned 5 min after initial rotation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 degrees counter-rotation learned 24 hr after initial rotation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased initial rotation learning
Number of subjects: 0
Study: 12092748

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin alone (20 mg/kg) in Rat Study 1
Number of subjects: 3

Group type: COMPARATOR
Intervention: Ciprofloxacin with calcium chloride (20 mg/kg) in Rat Study 2
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin alone (400 mg) in Study 1 (volunteer study)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Ciprofloxacin with calcium polycarbophil (400 mg + 1200 mg) in Study 2 (volunteer study)
Number of subjects: 3
Study: 10449024

Group type: EXPERIMENTAL
Intervention: Vertical Jump (VJ)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Long Jump (LJ)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Inclination angle of 75 degrees
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Inclination angle of 65 degrees
Number of subjects: 5
Study: 8672319

Group type: EXPERIMENTAL
Intervention: Propofol (0.01 EC50)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propofol (0.06 EC50)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propofol (0.13 EC50)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propofol (0.26 EC50)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Halothane (0 MAC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Halothane (0.05 MAC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Halothane (0.11 MAC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Halothane (0.2 MAC)
Number of subjects: 12
Study: 2310357

Group type: EXPERIMENTAL
Intervention: 8,000 ft (2,400 m) hypoxia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10,000 ft (3,000 m) hypoxia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 15,000 ft (4,500 m) hypoxia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 12,500 ft (3,800 m) hypoxia
Number of subjects: 40
Study: 392699

Group type: EXPERIMENTAL
Intervention: Fluoride supplement in sugar products (10 mg F as NaF per kg of sugar) and NaHCO3 + KH2PO4 mixture in candies (substituting for 2.5% of sugar).
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group received respective products without additives.
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Fluoride supplements in test subjects.
Number of subjects: 84
Study: 30244029

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 27664141

Group type: EXPERIMENTAL
Intervention: Community therapists delivering family therapy as routine standard of care
Number of subjects: 38
Study: 25679187

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg as atorvastatin calcium tablets
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 24
Study: 23944648

Group type: EXPERIMENTAL
Intervention: Intramyocardial injections of 2000 μg plasmid vascular endothelial growth factor 165
Number of subjects: 13
Study: 21900702

Group type: EXPERIMENTAL
Intervention: Novel EHR functionality
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Staff physicians
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Clinicians graduated more than 10 years ago
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Higher patient volumes
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: More documented patient problems
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Number of patient visits
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Number of documented problems
Number of subjects: 207
Study: 19250209

Group type: EXPERIMENTAL
Intervention: Traditional Mediterranean diet for 6 months
Number of subjects: 69
Study: 18051834

Group type: EXPERIMENTAL
Intervention: Chemoprevention
Number of subjects: 0
Study: 15473115

Group type: EXPERIMENTAL
Intervention: Active intervention (scheduled check-up by an occupational therapist using a checklist)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Standard intervention (user and carer encouraged to initiate contact when necessary)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Active intervention
Number of subjects: 216
Study: 11157143

Group type: EXPERIMENTAL
Intervention: IL‐1Ra 150 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IL‐1Ra 30 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12